Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
CAR-T for myeloma, impressive response rate, overall survival not reached.
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA
Author(s): Michele Cavo 1, Jesus San-Miguel 2, Saad Z Usmani 3, Katja Weisel 4, Meletios A Dimopoulos 5, Hervé Avet-Loiseau 6, Bruno Paiva 2, Nizar J Bahlis 7, Torben Plesner 8, Vania Hungria 9, Philippe Moreau 10, Maria-Victoria Mateos 11, Aurore Perrot 12, Shinsuke Iida 13, Thierry Facon 14, Shaji Kumar 15, Niels W C J van de Donk 16, Pieter Sonneveld 17, Andrew Spencer 18, Maria Krevvata 19, Christoph Heuck 19, Jianping Wang 20, Jon Ukropec 21, Rachel Kobos 19, Steven Sun 20, Mia Qi 20, Nikhil Munshi 22 23
Source: 2022 Feb 10;139(6):835-844. doi: 10.1182/blood.2021011101.
Dr. Lucio Gordan's Thoughts
MRD status in MM has unquestionable prognostic informational value, however many questions remain as how to address positive / negative MRD results. Should we de-escalate or stop Rx? When? Can we escalate Rx if + MRD? Which regimen, how long? It will be another few years till objective data are available. I do see value in at least having identification of clonality established upfront for tracking.
KEY POINTS
- Patients who are MRD negative with ≥CR have improved PFS, regardless of therapy, vs those who do not reach CR or are MRD positive.
- Daratumumab-based therapies lead to higher rates of ≥CR with MRD negativity compared with the standard of care.
VISUAL ABSTRACT
ABSTRACT
We explored minimal residual disease (MRD) in relapsed/refractory multiple myeloma (RRMM) and transplant-ineligible (TIE) newly diagnosed multiple myeloma (NDMM) using data from 4 phase 3 studies (POLLUX, CASTOR, ALCYONE, and MAIA). Each study previously demonstrated that daratumumab-based therapies improved MRD negativity rates and reduced the risk of disease progression or death by approximately half vs standards of care. We conducted a large-scale pooled analysis for associations between patients achieving complete response or better (≥CR) with MRD-negative status and progression-free survival (PFS). MRD was assessed via next-generation sequencing (10−5 sensitivity threshold). Patient-level data were pooled from all 4 studies and for patients with TIE NDMM and patients with RRMM who received ≤2 prior lines of therapy (≤2 PL). PFS was evaluated by response and MRD status. Median follow-up (months) was 54.8 for POLLUX, 50.2 for CASTOR, 40.1 for ALCYONE, and 36.4 for MAIA. Patients who achieved ≥CR and MRD negativity had improved PFS vs those who failed to reach CR or were MRD positive (TIE NDMM and RRMM hazard ratio [HR] 0.20, P < .0001; TIE NDMM and RRMM ≤2 PL HR 0.20, P < .0001). This benefit occurred irrespective of therapy or disease setting. A time-varying Cox proportional hazard model confirmed that ≥CR with MRD negativity was associated with improved PFS. Daratumumab-based treatment was associated with more patients reaching ≥CR and MRD negativity. These findings represent the first large-scale analysis with robust methodology to support ≥CR with MRD negativity as a prognostic factor for PFS in RRMM and TIE NDMM. These trials were registered at www.clinicaltrials.gov as #NCT02076009, #NCT02136134, #NCT02195479, and #NCT02252172.
Author Affiliations
1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy. 2Clínica Universidad de Navarra, Centro de Investigación Medica Aplicada (CIMA), IDISNA, CIBER-ONC, Pamplona, Spain. 3Levine Cancer Institute/Atrium Health, Charlotte, NC. 4Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 5National and Kapodistrian University of Athens, Athens, Greece. 6Unite de Genomique du Myelome, IUC-Oncopole, Toulouse, France. 7Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada. 8Vejle Hospital and University of Southern Denmark, Vejle, Denmark. 9Clinica Medica São Germano, São Paulo, Brazil. 10Hematology, University Hospital Hôtel-Dieu, CHU Nantes, Nantes, France. 11University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain. 12Hematology Department, University Cancer Institute IUCT, Toulouse, France. 13Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Mizuho-ku Nagoya, Japan. 14University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France. 15Department of Hematology, Mayo Clinic Rochester, Rochester, MN. 16Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. 17Erasmus MC, Rotterdam, The Netherlands. 18Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia. 19Janssen Research & Development, LLC, Spring House, PA. 20Janssen Research & Development, LLC, Raritan, NJ. 21Janssen Global Medical Affairs, Horsham, PA. 22Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and. 23Veterans Administration Boston Healthcare System, West Roxbury, MA.Related Articles
Teclistamab in Relapsed or Refractory Multiple Myeloma
The Bi-specific antibody era has started full-force with impressive results and reasonable toxicities, in different hematological neoplasms. Community oncology adoption of Bi-specific antibody will be successful, once standard operating procedures are in place, and multidisciplinary training takes place insofar as management of CRS. I am optimistic as to the uptake of this class of drugs in 1-2 years, pending payer coverage issues.
